Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Aspirin and secondary mortality after myocardial infarction

Elwood, Peter Creighton and Sweetnam, P. M. 1979. Aspirin and secondary mortality after myocardial infarction. The Lancet 314 (8156) , pp. 1313-1315. 10.1016/S0140-6736(79)92808-3

Full text not available from this repository.


A randomised controlled double-blind trial of aspirin in the prevention of death was conducted in 1682 patients (including 248 women) who had had a confirmed myocardial infarct (MI). 25% of the patients were admitted to the trial within 3 days of the infarction and 50% within 7 days. Aspirin, 300 mg three times daily, was given for 1 yr. Total mortality was 12·3% in patients given aspirin and 14·8% in those given placebo, a reduction by aspirin of 17%, which was not statistically significant at p<0·05. The reduction in specific ischæmic-heart-disease (IHD) mortality was 22% and in total mortality plus IHD morbidity (readmission to hospital for MI in survivors) was 28%.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Publisher: Elsevier
ISSN: 0140-6736
Last Modified: 04 Jun 2017 06:53

Citation Data

Cited 354 times in Google Scholar. View in Google Scholar

Cited 218 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item